BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gutpell KM, Tasevski N, Wong B, Hrinivich WT, Su F, Hadway J, Desjardins L, Lee TY, Hoffman LM. ANG1 treatment reduces muscle pathology and prevents a decline in perfusion in DMD mice. PLoS One 2017;12:e0174315. [PMID: 28334037 DOI: 10.1371/journal.pone.0174315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Xin C, Chu X, Wei W, Kuang B, Wang Y, Tang Y, Chen J, You H, Li C, Wang B. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice. Hum Mol Genet 2021;30:1349-59. [PMID: 33987645 DOI: 10.1093/hmg/ddab120] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Bosco J, Zhou Z, Gabriëls S, Verma M, Liu N, Miller BK, Gu S, Lundberg DM, Huang Y, Brown E, Josiah S, Meiyappan M, Traylor MJ, Chen N, Asakura A, De Jonge N, Blanchetot C, de Haard H, Duffy HS, Keefe D. VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy. Mol Ther Methods Clin Dev 2021;21:369-81. [PMID: 33898634 DOI: 10.1016/j.omtm.2021.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Podkalicka P, Mucha O, Dulak J, Loboda A. Targeting angiogenesis in Duchenne muscular dystrophy. Cell Mol Life Sci 2019;76:1507-28. [PMID: 30770952 DOI: 10.1007/s00018-019-03006-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
4 Starosta A, Konieczny P. Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. Cell Mol Life Sci 2021;78:4867-91. [PMID: 33825942 DOI: 10.1007/s00018-021-03821-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]